Veeva CTMS

์ž„์ƒ์‹œํ—˜ ๊ฐ€์‹œ์„ฑ ํ–ฅ์ƒ์œผ๋กœ ๋” ๋น ๋ฅด๊ณ  ์ •ํ™•ํ•œ ์˜์‚ฌ ๊ฒฐ์ • ์ง€์›

Veeva CTMS๋Š” ์ž์ฒด ์šด์˜ ๋ฐ ์•„์›ƒ์†Œ์‹ฑํ•˜๋Š” ์ž„์ƒ์‹œํ—˜์— ๋Œ€ํ•œ ํฌ๊ด„์ ์ธ ์ž„์ƒ์‹œํ—˜ ๊ด€๋ฆฌ ๋ฐ ๋ชจ๋‹ˆํ„ฐ๋ง ๊ธฐ๋Šฅ์„ ์ œ๊ณตํ•˜๋Š” ์—”ํ„ฐํ”„๋ผ์ด์ฆˆ ์ž„์ƒ์‹œํ—˜ ๊ด€๋ฆฌ ์‹œ์Šคํ…œ์ž…๋‹ˆ๋‹ค.

๋Œ€์‹œ๋ณด๋“œ ๋ฐ ๋ฆฌํฌํŠธ๋ฅผ ํ†ตํ•ด ์‹œํ—˜ ๋“ฑ๋ก ๋ฐ ๋งˆ์ผ์Šคํ†ค ๋“ฑ ์ฃผ์š” ์ง€ํ‘œ๋ฅผ ์‹ฌ์ธต ์ถ”์ ํ•˜๊ณ  ์ด์— ๋”ฐ๋ฅธ ์•ก์…˜์„ ์ทจํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ๋ชจ๋‹ˆํ„ฐ๋ง ๋ฐฉ๋ฌธ ๋ณด๊ณ ์„œ๋Š” ์ž๋™ํ™” ๋ฐ ๋™์  ์งˆ๋ฌธ ๋ถ„๊ธฐ ๊ธฐ๋Šฅ์ด ์ง€์›๋ฉ๋‹ˆ๋‹ค. ๋ฐฉ๋ฌธ ๋ณด๊ณ ์„œ๋Š” Veeva eTMF ๋‚ด์— ์ž๋™์œผ๋กœ ๋ณด๊ด€๋ฉ๋‹ˆ๋‹ค. ์ด์Šˆ์™€ ํ”„๋กœํ† ์ฝœ ์ผํƒˆ ๋ฐœ์ƒ ์‹œ ํ•„์š”์— ๋”ฐ๋ผ ๊ธฐ๋ก๋˜๋ฉฐ ๋ฌธ์ œ ํ•ด๊ฒฐ ์›Œํฌํ”Œ๋กœ์šฐ๋ฅผ ํ†ตํ•ด ์ „๋‹ฌ๋˜์–ด ์ข…๊ฒฐ๋ฉ๋‹ˆ๋‹ค. CTMS Transfer ๊ธฐ๋Šฅ์€ Veeva CTMS๋ฅผ ์‚ฌ์šฉํ•˜๋Š” CRO์™€ ์Šคํฐ์„œ ๊ฐ„์˜ ๋ฐ์ดํ„ฐ ์ผ์ผ ์ „์†ก์„ ์ž๋™ํ™”ํ•ฉ๋‹ˆ๋‹ค.

Veeva CTMS๋Š” Veeva EDC์™€ ์—ฐ๊ฒฐ๋˜์–ด ๋“ฑ๋ก, ๋ชจ๋‹ˆํ„ฐ๋ง, ์‚ฌ์ดํŠธ ์—ฐ๊ตฌ๋น„ ์ง€๊ธ‰ ๋ฐ ์ผ€์ด์Šค๋ถ ํƒ์ƒ‰ ๋“ฑ Veeva CTMS ๋‚ด์—์„œ ์ง์ ‘์ ์ธ ์•ก์„ธ์Šค๋ฅผ ์ง€์›ํ•ฉ๋‹ˆ๋‹ค. ์ž„์ƒ ์—ฐ๊ตฌ์ž์™€์˜ ์ƒํ˜ธ์ž‘์šฉ ์ •๋ณด๊ฐ€ CRM๊ณผ ๋™๊ธฐํ™”๋˜์–ด ์ข…ํ•ฉ์ ์ธ 360๋„ ๊ด€์ ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค.

Announced 2016 Status Very Mature Customers 100+
์ œํ’ˆ ์†Œ๊ฐœ์„œ ๋‹ค์šด๋ฐ›๊ธฐ
Veeva CTMS
๋ฐ”์ด์˜ค์ œ์•ฝ์‚ฌ๋ผ๋ฉด CTMS๋ฅผ ๋„์ž…ํ•ด์•ผ ํ•˜๋Š” ์ด์œ 
์ฃผ์š” ์„ฑ๊ณผ

์œ ์—ฐํ•œ ๋‹จ์ผ ์‹œ์Šคํ…œ์— ๋ฐ์ดํ„ฐ์™€ ๋ฌธ์„œ๋ฅผ ์ค‘์•™ํ™”ํ•˜์„ธ์š”

30%

๋ชจ๋‹ˆํ„ฐ๋ง ๋น„์šฉ ์ ˆ๊ฐ

50%

๋ฐฉ๋ฌธ ๋ณด๊ณ ์„œ ์ž‘์„ฑ ์‹œ๊ฐ„ ์ ˆ์•ฝ

80%

์ด์Šˆ ํŒŒ์•… ์†๋„ ๊ฐœ์„ 

Veeva CTMS๋ฅผ ์„ ํƒํ•ด์•ผ ํ•˜๋Š” ์ด์œ 

๋” ๋น ๋ฅด๊ณ  ๋†’์€ ํ’ˆ์งˆ์˜ ์ž„์ƒ์‹œํ—˜

์ƒ์‚ฐ์„ฑ ํ–ฅ์ƒ

๋ชจ๋‹ˆํ„ฐ๋ง์— ์†Œ์š”๋˜๋Š” ์‹œ๊ฐ„์„ ์ค„์—ฌ ์ž„์ƒ์‹œํ—˜ ๋น„์šฉ์„ ์ ˆ๊ฐํ•ฉ๋‹ˆ๋‹ค.

์„ ์ œ์ ์ธ ์˜์‚ฌ ๊ฒฐ์ • ์ง€์›

์ž„์ƒ์‹œํ—˜์— ๋Œ€ํ•œ 360๋„ ์ข…ํ•ฉ์ ์ธ ๋ทฐ๋ฅผ ํ™•๋ณดํ•˜๊ณ , ํ™œ๋™์„ ์ž๋™ํ™”ํ•˜๋ฉฐ, ์ง€์—ฐ์„ ์™„ํ™”ํ•˜์—ฌ ์ž„์ƒ์‹œํ—˜ ์‹คํ–‰์„ ์ตœ์ ํ™”ํ•ฉ๋‹ˆ๋‹ค.

์Šคํฐ์„œ-CRO ํ˜‘์—… ๊ฐœ์„ 

ํฌํŠธํด๋ฆฌ์˜ค ์„ฑ๊ณผ๋ฅผ ๋ชจ๋‹ˆํ„ฐ๋งํ•˜์—ฌ ๋™ํ–ฅ์„ ํŒŒ์•…ํ•˜๊ณ , CTMS ๋ฐ์ดํ„ฐ๋ฅผ ์ž๋™ ์ „์†กํ•˜๋ฉฐ, ์„ ์ œ์ ์ธ ์•ก์…˜์„ ์ง€์›ํ•ฉ๋‹ˆ๋‹ค.

๊ทœ์ • ์ค€์ˆ˜ ๊ฐ•ํ™”

๋ฐ์ดํ„ฐ์™€ ๋ฌธ์„œ๋ฅผ ๋‹จ์ผ ํ†ตํ•ฉ ์‹œ์Šคํ…œ์— ์ง‘์ค‘ํ™”ํ•˜์—ฌ ICH ๊ทœ์ • ์ค€์ˆ˜๋ฅผ ์œ ์ง€ํ•ฉ๋‹ˆ๋‹ค.

๊ณ ๊ฐ ์„ฑ๊ณต ์‚ฌ๋ก€

200๊ฐœ ์ด์ƒ์˜ ์Šคํฐ์„œ์™€ CRO๊ฐ€
CTMS๋ฅผ ํ†ตํ•ด ์ž„์ƒ์‹œํ—˜ ๊ด€๋ฆฌ๋ฅผ ๊ฐ„์†Œํ™”ํ•ฉ๋‹ˆ๋‹ค

Astellas Bayer Boehringer Ingelheim CSL Ferring Fortrea GSK Novo Nordisk Parelex Syneos Vertex

“์—ฐ๊ตฌ ํŒ€์ด ์ฒด๊ฐํ•˜๋Š” ๊ฐ€์žฅ ํฐ ๋ณ€ํ™”๋Š” ๋‹จ์ผ ์‹œ์Šคํ…œ์—์„œ ์ž‘์—…ํ•œ๋‹ค๋Š” ์ ์ž…๋‹ˆ๋‹ค.
์‹œํ—˜๊ธฐ๊ด€ ๋ฐฉ๋ฌธ ๋ณด๊ณ ์„œ๋ฅผ ์ž‘์„ฑํ•˜๋ฉด, ํ•ด๋‹น ๋ณด๊ณ ์„œ๊ฐ€ eTMF๋กœ ์ž๋™์œผ๋กœ ์ „์†ก๋ฉ๋‹ˆ๋‹ค.”

Tony Lewis, Director, Trial Operations Product Owner
GSK
๋” ์ž์„ธํžˆ ์•Œ์•„๋ณด๊ธฐ

“Veeva CTMS์™€ eTMF ๋•๋ถ„์— ์ €ํฌ๋Š” ์›ํ™œํ•˜๊ฒŒ ํ†ตํ•ฉ๋˜์–ด
ํšŒ์‚ฌ ์ „๋ฐ˜์ ์œผ๋กœ ํ™œ์šฉ ๊ฐ€๋Šฅํ•œ ํ”Œ๋žซํผ์„ ๊ฐ–์ถ”๊ฒŒ ๋˜์—ˆ์Šต๋‹ˆ๋‹ค.”

John McAdory, Vice President, Clinical Operations
CG Oncology
๊ณ ๊ฐ ์˜์ƒ ์‹œ์ฒญํ•˜๊ธฐ

“์ €ํฌ๋Š” ๋ชจ๋“  ๊ธฐ๋Šฅ์„ ๊ฐ–์ถ˜ CTMS๋ฅผ ๋ณด์œ ํ•˜๊ฒŒ ๋˜์—ˆ์œผ๋ฉฐ,
์šด์˜ ๋ฐ์ดํ„ฐ๋ฅผ ์ œ๋Œ€๋กœ ๊ด€๋ฆฌํ•˜๊ณ  ํ™œ์šฉํ•  ์ˆ˜ ์žˆ๋Š” ๊ถŒํ•œ์„ ํ™•๋ณดํ–ˆ์Šต๋‹ˆ๋‹ค.”

Nick Kurkjy, Operational Data Project Lead for Clinical Trials
Takeda
๋” ์ž์„ธํžˆ ์•Œ์•„๋ณด๊ธฐ
๋ฆฌ์†Œ์Šค

์ž์„ธํžˆ ์‚ดํŽด๋ณด๊ธฐ

๊ธฐ๋Šฅ ์†Œ๊ฐœ์„œ
Veeva CTMS ๊ธฐ๋Šฅ ์†Œ๊ฐœ์„œ
eBook ๋ณด๊ธฐ
๋ฐ”์ด์˜ค์ œ์•ฝ์‚ฌ๊ฐ€ CTMS๋ฅผ ๋„์ž…ํ•ด์•ผ ํ•˜๋Š” ๊ฒฐ์ •์ ์ธ ์ด์œ 
๊ณ ๊ฐ ์˜์ƒ ๋ณด๊ธฐ
GSK์˜ ์ž„์ƒ ์‹œํ—˜ ๊ธฐ๊ด€ ๋ชจ๋‹ˆํ„ฐ๋ง ํšจ์œจํ™” ๋ฐฉ์•ˆ
๊ณ ๊ฐ ์˜์ƒ ๋ณด๊ธฐ
Jazz Pharmaceuticals, eTMF์™€ CTMS ํ†ตํ•ฉ์œผ๋กœ ํšจ์œจ์„ฑ ๊ทน๋Œ€ํ™”
์ผ€์ด์Šค ์Šคํ„ฐ๋”” ๋ณด๊ธฐ
๊ธ€๋กœ๋ฒŒ ์ƒ์œ„ 20 ์ œ์•ฝ์‚ฌ: CTMS ํ˜์‹  ๋ชจ๋ฒ” ์‚ฌ๋ก€
์•„ํ‹ฐํด ๋ณด๊ธฐ
Recordati, Veeva ์ค‘์•™ ์ง‘์ค‘์‹ ๊ฐ๋… ์‹œ์Šคํ…œ์œผ๋กœ ๋ฌธ์„œ ๋ผ์ดํ”„์‚ฌ์ดํด ์‹œ๊ฐ„ 25% ๋‹จ์ถ•
๊ณ ๊ฐ ์‚ฌ๋ก€ ๋ณด๊ธฐ
CG Oncology, ์ž„์ƒ์‹œํ—˜ ๊ด€๋ฆฌ ์ ‘๊ทผ ๋ฐฉ์‹ ํ˜„๋Œ€ํ™”
๋ฐ๋ชจ ์˜์ƒ ๋ณด๊ธฐ
CTMS Transfer ์‹ค์ œ ์ž‘๋™๋ฒ• ํ™•์ธํ•˜๊ธฐ
์˜์ƒ ๋ณด๊ธฐ
Veeva CTMS๋ฅผ ํ†ตํ•œ ์ž„์ƒ์‹œํ—˜ ๊ด€๋ฆฌ ๊ฐ„์†Œํ™”

๋” ์ž์„ธํ•œ ๋‚ด์šฉ์ด ๊ถ๊ธˆํ•˜์‹ ๊ฐ€์š”?

๋ฌธ์˜ํ•˜๊ธฐ ์ œํ’ˆ ์†Œ๊ฐœ์„œ ๋‹ค์šด๋ฐ›๊ธฐ